Theranostics and radiopharmaceutical therapies are rapidly transforming the medical landscape, and the neuro-oncology community is observing these developments with great interest. In a field characte ...
Fibroblast activation protein (FAP), a member of the serine protease family, is expressed in the microenvironment of more than 90% of epithelial tumors, including pancreas, colon, breast, and ENT (ear ...
The aim of this study was to evaluate the physical performance of the Vereos whole-body PET/CT system according to the National Electrical Manufacturers Association (NEMA) NU2-2012 standard and to ...
Irène Buvat, PhD, Centre National de la Recherche Scientifique director of research and head of the Inserm Laboratory of Translational Imaging in Oncology at the Institut Curie, Orsay (France), and ...
Journal of Nuclear Medicine July 2025, jnumed.125.270167; DOI: https://doi.org/10.2967/jnumed.125.270167 ...
Prostate cancer is the most common cancer diagnosis in men in the United States and a leading cause of cancer-related morbidity and mortality (1). It can exist along a wide spectrum of aggressiveness ...
Journal of Nuclear Medicine October 2025, jnumed.125.270804; DOI: https://doi.org/10.2967/jnumed.125.270804 ...
Journal of Nuclear Medicine October 2025, jnumed.125.270825; DOI: https://doi.org/10.2967/jnumed.125.270825 ...
Osteosarcoma is a malignant bone tumor with very limited therapeutic options ( [ 1 ] [1]). However, targeting the frequently overexpressed disialoganglioside GD2 was successful in preclinical studies ...
Despite significant advancements in medical and device-based therapies, cardiovascular disease remains the number one cause of death in the United States. Early detection of atherosclerosis, ...
The development of novel multimodality imaging agents and techniques represents the current frontier of research in the field of medical imaging science. However, the combination of nuclear tomography ...
From Compassionate Use Toward High-Level Evidence for Radiopharmaceutical Therapy in Recurrent Meningioma: The LUMEN-1 and MOMENTUM-1 Trials ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback